{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:48:45Z","timestamp":1782906525238,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute hepatitis B virus (HBV) infection encompasses a broad clinical spectrum, from self-limited hepatitis to acute liver injury (ALI), acute liver failure (ALF), subacute liver failure, and ALF on chronic HBV reactivation. This study investigates how host and viral factors interact to shape the clinical spectrum of HBV-associated ALF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 231 serial serum samples from 49 well-characterized patients including 36 with HBV-associated ALF and 13 with acute hepatitis B. Among ALF patients, 7 had ALI, 7 acute and 11 subacute liver failure, and 11 ALF on chronic HBV. Viral factors, including HBV replication, genotype, sequence diversity and viral evolution by next-generation sequencing (NGS) were assessed alongside host immune responses and cytokine profiles by proteomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Demographics were similar across groups. Mortality was highest in subacute liver failure and ALF on chronic HBV (82%) and intermediate in acute liver failure (43%). The three forms of ALF differed by clinical, virologic, and immunologic features. Acute liver failure was characterized by markedly elevated alanine aminotransferase and high IgM anti-HBc titers, whereas ALF on CHB showed higher serum HBV DNA, HBV RNA and HBcrAg levels. HBV genotype A predominated (63%), followed by D (15%), C (9%), and others (2\u20136%). NGS of the basal core promoter and precore\/core regions revealed highly homogeneous viral populations in acute and subacute liver failure throughout follow-up, while ALF on CHB showed marked viral heterogeneity. Genetic diversity was genotype-dependent, unrelated to disease severity, and significantly lower in genotype A than D. Acute liver failure was associated with broad type 1 cytokine response (i.e. IP-10, MIP-1\u03b1, MIP-1\u03b2, TNF-\u03b1, and IFN-\u03b3), restricted type 2 cytokine response (i.e. IL-4 and sCD137), along with proinflammatory (i.e. MCP-1, Il-6, and IL-8) and homeostatic (i.e. IL-7) cytokines, whereas subacute liver failure and ALF on chronic HBV exhibited low and restricted, but distinct cytokine profiles. Elevated GM-CSF and PDGF-BB at admission predicted transplant-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Distinct clinical, serologic, virologic, and cytokine profiles correlate with disease severity, highlighting differing pathogenic mechanisms across HBV-associated ALF forms. Early biomarkers, including GM-CSF and PDGF-BB, may help predict recovery and guide individualized management to improve survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08347-z","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:15:11Z","timestamp":1782393311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of viral and host factors in determining the outcome of HBV-associated acute liver failure"],"prefix":"10.1186","volume":"24","author":[{"given":"Patrizia","family":"Farci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide De","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Raini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Follman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"9","key":"8347_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"C Gbdhb","year":"2022","unstructured":"Gbdhb C. Global, regional, and national burden of hepatitis B, 1990-2019. A systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829. https:\/\/doi.org\/10.1016\/S2468-1253(22)00124-8.","journal-title":"LancetThe Lancet Gastroenterol &amp; Hepatol"},{"issue":"10454","key":"8347_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(24)00693-7","volume":"404","author":"R Maiwall","year":"2024","unstructured":"Maiwall R, Kulkarni AV, Arab JP, Piano S. Acute liver failure. Lancet. 2024;404(10454):789\u2013802. https:\/\/doi.org\/10.1016\/S0140-6736(24)00693-7.","journal-title":"Lancet"},{"issue":"1","key":"8347_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68\u201376.","journal-title":"J Virol"},{"issue":"1","key":"8347_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","volume":"1","author":"LG Guidotti","year":"2006","unstructured":"Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis. 2006;1(1):23\u201361. https:\/\/doi.org\/10.1146\/annurev.pathol.1.110304.100230.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"19","key":"8347_CR5","doi-asserted-by":"publisher","first-page":"8766","DOI":"10.1073\/pnas.1003854107","volume":"107","author":"P Farci","year":"2010","unstructured":"Farci P, Diaz G, Chen Z, et al. B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci USA. 2010;107(19):8766\u201371. https:\/\/doi.org\/10.1073\/pnas.1003854107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8347_CR6","doi-asserted-by":"publisher","unstructured":"Chen Z, Diaz G, Pollicino T, et al. Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. Proc Natl Acad Sci USA. 2018;115(48):E11369\u201378. https:\/\/doi.org\/10.1073\/pnas.1809028115.","DOI":"10.1073\/pnas.1809028115"},{"issue":"1","key":"8347_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cgh.2014.06.028","volume":"13","author":"MG Ghany","year":"2015","unstructured":"Ghany MG, Perrillo R, Li R, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015;13(1):183\u201392. https:\/\/doi.org\/10.1016\/j.cgh.2014.06.028.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"8347_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/hep.24732","volume":"55","author":"DY Dao","year":"2012","unstructured":"Dao DY, Hynan LS, Yuan HJ, et al. Two distinct subtypes of hepatitis B virus\u2013related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology. 2012;55(3):676\u201384. https:\/\/doi.org\/10.1002\/hep.24732.","journal-title":"Hepatology"},{"issue":"9","key":"8347_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41395-018-0160-2","volume":"113","author":"DR Ganger","year":"2018","unstructured":"Ganger DR, Rule J, Rakela J, et al. Acute liver failure of indeterminate etiology: a comprehensive systematic approach by an expert committee to establish causality. Am J Gastroenterol. 2018;113(9):1319. https:\/\/doi.org\/10.1038\/s41395-018-0160-2.","journal-title":"Am. J. Gastroenterol"},{"issue":"8","key":"8347_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00535-012-0624-x","volume":"47","author":"K Sugawara","year":"2012","unstructured":"Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47(8):849\u201361. https:\/\/doi.org\/10.1007\/s00535-012-0624-x.","journal-title":"J Gastroenterol"},{"key":"8347_CR11","doi-asserted-by":"publisher","unstructured":"Engle RE, De Battista D, Danoff EJ, et al. Distinct cytokine profiles correlate with disease severity and outcome in longitudinal studies of acute hepatitis B virus and hepatitis D virus infection in chimpanzees. mBio. 2020;11(6). https:\/\/doi.org\/10.1128\/mBio.02580-20.","DOI":"10.1128\/mBio.02580-20"},{"issue":"11","key":"8347_CR12","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1111\/trf.12682","volume":"54","author":"RE Engle","year":"2014","unstructured":"Engle RE, Bukh J, Alter HJ, et al. Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors. Transfusion. 2014;54(11):2833\u201341. https:\/\/doi.org\/10.1111\/trf.12682.","journal-title":"Transfusion"},{"issue":"9","key":"8347_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1541-7786.MCR-18-0012","volume":"16","author":"G Diaz","year":"2018","unstructured":"Diaz G, Engle RE, Tice A, et al. Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma. Mol Cancer Res. 2018;16(9):1406\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0012.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"8347_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/j.0006-341X.2001.01198.x","volume":"57","author":"MP Fay","year":"2001","unstructured":"Fay MP, Graubard BI. Small-sample adjustments for Wald-type tests using sandwich estimators. Biometrics. 2001;57(4):1198\u2013206. https:\/\/doi.org\/10.1111\/j.0006-341X.2001.01198.x.","journal-title":"Biometrics"},{"issue":"5","key":"8347_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/gutjnl-2011-300832","volume":"61","author":"Y Tamada","year":"2012","unstructured":"Tamada Y, Yatsuhashi H, Masaki N, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 2012;61(5):765\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2011-300832.","journal-title":"Gut"},{"issue":"4","key":"8347_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.7326\/0003-4819-105-4-546","volume":"105","author":"KM De Cock","year":"1986","unstructured":"De Cock KM, Govindarajan S, Valinluck B, Redeker AG. Hepatitis B virus DNA in fulminant hepatitis B. Ann Intern Med. 1986;105(4):546\u201347. https:\/\/doi.org\/10.7326\/0003-4819-105-4-546.","journal-title":"Ann Intern Med"},{"issue":"24","key":"8347_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJM199106133242405","volume":"324","author":"TJ Liang","year":"1991","unstructured":"Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med. 1991;324(24):1705\u201309. https:\/\/doi.org\/10.1056\/NEJM199106133242405.","journal-title":"N Engl J Med"},{"issue":"4","key":"8347_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/0016-5085(91)90286-T","volume":"100","author":"Y Kosaka","year":"1991","unstructured":"Kosaka Y, Takase K, Kojima M, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology. 1991;100(4):1087\u201394. https:\/\/doi.org\/10.1016\/0016-5085(91)90286-T.","journal-title":"Gastroenterology"},{"issue":"24","key":"8347_CR19","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJM199106133242404","volume":"324","author":"M Omata","year":"1991","unstructured":"Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991;324(24):1699\u2013704. https:\/\/doi.org\/10.1056\/NEJM199106133242404.","journal-title":"N Engl J Med"},{"issue":"4","key":"8347_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-122-4-199502150-00001","volume":"122","author":"S Sato","year":"1995","unstructured":"Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med. 1995;122(4):241\u201348. https:\/\/doi.org\/10.7326\/0003-4819-122-4-199502150-00001.","journal-title":"Ann Intern Med"},{"issue":"9","key":"8347_CR21","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1128\/jvi.67.9.5402-5410.1993","volume":"67","author":"JS Li","year":"1993","unstructured":"Li JS, Tong SP, Wen YM, et al. Hepatitis B virus genotype a rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol. 1993;67(9):5402\u201310. https:\/\/doi.org\/10.1128\/jvi.67.9.5402-5410.1993.","journal-title":"J Virol"},{"issue":"6","key":"8347_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/hep.1840220605","volume":"22","author":"F Rodriguez-Frias","year":"1995","unstructured":"Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology. 1995;22(6):1641\u201347. https:\/\/doi.org\/10.1002\/hep.1840220605.","journal-title":"Hepatology"},{"issue":"3","key":"8347_CR23","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/hep.510290352","volume":"29","author":"HL Chan","year":"1999","unstructured":"Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 1999;29(3):976\u201384.","journal-title":"Hepatology"},{"issue":"1","key":"8347_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0168-8278(05)80019-4","volume":"18","author":"C Feray","year":"1993","unstructured":"Feray C, Gigou M, Samuel D, Bernuau J, Bismuth H, Br\u00e9chot C. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Educ Chang Hepatol. 1993;18(1):119\u201322. https:\/\/doi.org\/10.1016\/S0168-8278(05)80019-4.","journal-title":"J Educ Chang Hepatol"},{"issue":"11","key":"8347_CR25","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/gut.52.11.1630","volume":"52","author":"T Imamura","year":"2003","unstructured":"Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003;52(11):1630\u201337. https:\/\/doi.org\/10.1136\/gut.52.11.1630.","journal-title":"Gut"},{"issue":"1","key":"8347_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev-pathmechdis-042524-030646","volume":"21","author":"J Lin","year":"2025","unstructured":"Lin J, Gehring AJ. Role of immune cells in hepatitis B virus and associated sequelae. Annu Rev Pathol. 2025;21(1):399\u2013421. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-042524-030646.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"8347_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","volume":"13","author":"FV Chisari","year":"1995","unstructured":"Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995;13(1):29\u201360. https:\/\/doi.org\/10.1146\/annurev.iy.13.040195.000333.","journal-title":"Annu. Rev. Immunol"},{"issue":"5415","key":"8347_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"284","author":"LG Guidotti","year":"1999","unstructured":"Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284(5415):825\u201329. https:\/\/doi.org\/10.1126\/science.284.5415.825.","journal-title":"Science"},{"issue":"1","key":"8347_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","volume":"150","author":"Y Xia","year":"2016","unstructured":"Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, H\u00f6sel M, et al. Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150(1):194\u2013205. https:\/\/doi.org\/10.1053\/j.gastro.2015.09.026.","journal-title":"Gastroenterology"},{"issue":"380","key":"8347_CR30","doi-asserted-by":"publisher","first-page":"123948","DOI":"10.1016\/j.lfs.2025.123948","volume":"380","author":"Z Yang","year":"2025","unstructured":"Yang Z, Zhang J, Wang Q, et al. A PBX1-IL7R axis mediates liver fibrosis in non-alcoholic fatty liver disease. Life Sci. 2025;380(380):123948. https:\/\/doi.org\/10.1016\/j.lfs.2025.123948.","journal-title":"Life Sci"},{"key":"8347_CR31","doi-asserted-by":"publisher","unstructured":"Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol. 2018;3(25). https:\/\/doi.org\/10.1126\/sciimmunol.aat1604.","DOI":"10.1126\/sciimmunol.aat1604"},{"issue":"3","key":"8347_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/hep.23754","volume":"52","author":"A Dechene","year":"2010","unstructured":"Dechene A, Sowa JP, Gieseler RK, et al. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell Activation\u2020. Hepatology. 2010;52(3):1008\u201316. https:\/\/doi.org\/10.1002\/hep.23754.","journal-title":"Hepatology"},{"key":"8347_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fphys.2012.00213","volume":"3","author":"Y Saiman","year":"2012","unstructured":"Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physio. 2012;3:213. https:\/\/doi.org\/10.3389\/fphys.2012.00213.","journal-title":"Front Physio"},{"key":"8347_CR34","doi-asserted-by":"publisher","first-page":"619039","DOI":"10.3389\/fimmu.2020.619039","volume":"11","author":"E Weiss","year":"2021","unstructured":"Weiss E, de la Grange P, Defaye M, et al. Characterization of blood immune cells in patients with decompensated cirrhosis including ACLF. Front Immunol. 2021;11:619039. https:\/\/doi.org\/10.3389\/fimmu.2020.619039.","journal-title":"Front Immunol"},{"key":"8347_CR35","doi-asserted-by":"publisher","first-page":"620365","DOI":"10.3389\/fimmu.2021.620365","volume":"12","author":"W Wu","year":"2021","unstructured":"Wu W, Sun S, Wang Y, et al. Circulating neutrophil dysfunction in HBV-Related acute-on-chronic liver failure. Front Immunol. 2021;12:620365. https:\/\/doi.org\/10.3389\/fimmu.2021.620365.","journal-title":"Front Immunol"},{"issue":"1","key":"8347_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.24673","volume":"55","author":"F Meng","year":"2012","unstructured":"Meng F, Francis H, Glaser S, et al. Role of stem cell factor and granulocyte colony\u2013stimulating factor in remodeling during liver regeneration. Hepatology. 2012;55(1):209\u201321. https:\/\/doi.org\/10.1002\/hep.24673.","journal-title":"Hepatology"},{"issue":"8","key":"8347_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/jir.2014.0149","volume":"35","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya P, Budnick I, Singh M, et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res. 2015;35(8):585\u201399. https:\/\/doi.org\/10.1089\/jir.2014.0149.","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"8347_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","volume":"12","author":"IP Wicks","year":"2016","unstructured":"Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 2016;12(1):37\u201348. https:\/\/doi.org\/10.1038\/nrrheum.2015.161.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"8347_CR39","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1172\/JCI66369","volume":"123","author":"C Yin","year":"2013","unstructured":"Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 2013;123(5):1902\u201310. https:\/\/doi.org\/10.1172\/JCI66369.","journal-title":"J. Clin. Invest"},{"issue":"7","key":"8347_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8347_CR41","doi-asserted-by":"publisher","unstructured":"Patel NH, Chen AY, Osiowy C, et al. Hepatitis B virus variants and cytokine patterns in acute liver failure and transplant-free survival. Liver Int. 2025;45(7):e70175. https:\/\/doi.org\/10.1111\/liv.70175.","DOI":"10.1111\/liv.70175"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08347-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08347-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:16:05Z","timestamp":1782904565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08347-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8347"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08347-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Institutional Review Board. Participants were enrolled after obtaining informed consent from either the patients themselves or their legal next of kin. The study was conducted in strict accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"William M. Lee discloses the following: consulting for Genentech, Pfizer, GSK, RAPT, Lighthouse Pharma and Veristat; receives research support from Gilead, Alexion, Camurus, Lipocine, Akero and Madrigal, none related to the current manuscript. The remaining authors disclose no conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"836"}}